ERBB2 and neoplasm: mAbs can inhibit tumor growth by several mechanisms: (i) activation of antibody-dependent cellular cytotoxicity (ADCC) driven by Fc-recognizing cells such as NK cells, (ii) tumor growth inhibition by blocking important cellular receptors with mAbs (e.g. blocking EGFR or HER2/neu) and (iii) activation of the immune system by blocking immune inhibitory receptors with mAbs (e.g. immune checkpoint inhibition therapy) 94.